Markets Stocks Economy Crypto Earnings Banking Energy
Home› Stocks› Feature
Stocks · Exclusive

Sylvamo's Europe exit sharpens its focus on the Americas

Sylvamo's Europe exit sharpens its focus on the Americas
Stocks · 2026
Photo · Marcus Devlin for Daily Digest Invest
By Marcus Devlin Equities Correspondent Nov 9, 2026 4 min read

Sylvamo, the paper maker that split from International Paper in 2021, is selling its European business to Midas Atlantic Partners and The Najafi Cos. The deal, expected to close in the first quarter of 2027, marks a strategic retreat from a region that has been a persistent drag on the company's earnings. RBC Capital Markets analysts say the exit should finally stop the losses that have weighed on Sylvamo's overall results.

Why Europe was a problem

Running a paper business in Europe has become increasingly costly and competitive. Sylvamo's European mills required significant maintenance spending, and the operation was losing money. By selling it, Sylvamo not only sheds those losses but also reduces the capital expenditure needed to keep the plants running. RBC's view is that this sharpens the company's focus on the Americas, where its mills are stronger and more efficient.

The sale also includes a sweetener: Sylvamo will retain rights to 20% of future cash distributions from the business. That means it can still benefit from any turnaround in Europe without having to manage the day-to-day operations. It's a way to keep a foot in the door while cutting the costs.

The North American import problem

But the story doesn't end with Europe. Sylvamo's results are still closely tied to North American uncoated freesheet (UFS) paper, the kind used in offices and publishing. This is a commodity-like product, and when the market is oversupplied, the price tends to be set by the cheapest available tons. Right now, those cheapest tons are increasingly coming from imports.

RBC flagged that September imports of UFS paper were up 93.4% from a year earlier, with net imports reaching 19.5% of consumption. That's a massive jump, and it's making it hard for domestic producers like Sylvamo to raise prices. In this environment, internal efficiency moves can help protect margins, but they rarely lead to a big step up in profitability until the import pressure eases.

What it means for investors

RBC raised its price target on Sylvamo to $37 from $35, even though the stock is trading around $38.78. That gap shows how much of the story now depends on factors outside the company's control. If imports keep setting the market price, Sylvamo's post-Europe cost savings are more likely to show up as margin protection than as meaningfully higher prices.

That's why RBC sticks with a 'sector perform' rating. The cleaner operations are a positive, but the near-term earnings driver is whether that 93.4% import jump proves temporary or becomes the new normal. If imports cool, Sylvamo could see a real boost. If they don't, the company may have to rely on cost cuts alone to keep profits stable.

For everyday investors, this is a reminder that even good strategic moves can be overshadowed by broader market forces. Sylvamo's decision to exit Europe is a sensible step to cut losses and focus on its strengths. But the company's fate is still tied to a paper market that's being flooded by cheaper imports. Until that pressure fades, the upside may be limited.

Investors should also keep an eye on how the sale proceeds are used. The company could use the cash to pay down debt, return money to shareholders, or invest in its remaining operations. Any of those could be positive, but the import situation remains the key variable.

In the meantime, the broader paper industry is watching closely. If Sylvamo's European exit works, other companies with similar operations might consider similar moves. But the import issue is a reminder that global trade flows can quickly change the math for domestic producers.

For now, RBC's $37 target suggests the stock is fairly valued, and the market seems to agree. The real test will come in the next few quarters, as investors see whether the import surge is a blip or a lasting trend.

More from this story

Next article · Don't miss

Biotech stocks Faeth, Abeona slide; Nvidia drops on CEO probe

Two small biotechs tumbled on company-specific updates, and Nvidia fell after launching an internal probe linked to reports about CEO Jensen Huang. Here's what investors should watch.

Read the story →
Biotech stocks Faeth, Abeona slide; Nvidia drops on CEO probe